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Background 
Strategies to improve outcomes in cancer patients are underpinned by accurate 
recording of high quality data in a standard format. ‘Ovarian’ cancer, of which by far 
the most common subtype is high-grade serous carcinoma (HGSC), constitutes the 
second commonest gynecologic malignancy and overwhelmingly the one with the 
highest mortality. Despite some advances in prevention, early detection, surgery and 
chemotherapy, the mortality rate has not decreased significantly. This makes accurate 
and uniform data recording essential for monitoring the impact of new strategies, both 
in clinical practice and trial settings. 
 
There have been significant recent developments in our understanding and approach 
to the classification of HGSC. The FIGO 2014 staging system commendably unifies 
the staging of primary ovarian, tubal and peritoneal cancers (1). While this is 
accompanied by the mandate that primary site must be assigned as tubal, ovarian, 
peritoneal or undesignated, no guidance is offered for assigning primary site. In the 
World Health Organisation (WHO) 2014 classification of tumors of the female genital 
tract, site assignment is left to the ‘experience and professional judgment’ of the 
reporting pathologist/tumor board (2). The WHO classification has also altered the 
criteria for making a diagnosis of primary peritoneal carcinoma (PPC). Previously 
broadly defined by size criteria, PPC is currently defined as peritoneal HGSC when 
both tubes and ovaries are grossly and microscopically normal (or enlarged by benign 
disease), a change of which practitioners should be made universally aware (2). A 
further major significant development is the evidence that has accumulated over the 
last 15 years that the majority of non-uterine HGSC arise in the fimbrial end of the 
fallopian tube and not the ovary (3). However, there is variation in the awareness and 
acceptance of this evidence. 
 
In the absence of a defined and agreed protocol, all of the above threaten to produce at 
least three areas of potential discrepancy in the way HGSC is classified by different 
individuals/tumor boards: one is the classification of tubal versus ovarian, the second 
the diagnosis of PPC and the third the likelihood of significant numbers of cases 
being classified as ‘undesignated’. This in turn could impact on data collected by 
cancer registries and produce artificial regional and national differences. The authors 
of this document propose the adoption of a unified approach to site assignment in 
tubo-ovarian HGSC. 
 
Pivotal to this approach is the evidence supporting a tubal origin in the large majority 
of cases. Findings in risk-reducing salpingo-oophorectomy specimens (RRSO) have 
established serous tubal intraepithelial carcinoma (STIC) to be the earliest lesion in 
familial cases (4). Insights gained from RRSO specimens rejuvenated the quest for 
precursors in sporadic cases of HGSC. These early microscopic lesions are almost 
invariably located within the epithelium covering the fimbrial end of the tube, an area 
that was not routinely sampled for histological examination prior to this discovery. As 
a result, more detailed sampling of the tube has been widely adopted using a protocol 
that maximizes microscopic examination of the fimbrial epithelium (SEE-FIM: 
Sectioning and Extensively Examining the FIMbria (4); an essential step in detection 
of these lesions.  
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In the past, the microscopic nature of STIC, its location requiring detailed sampling of 
the fimbrial end of the tube and the tendency for HGSC to present at high clinical 
stage when any precursors have been overgrown all made it difficult to demonstrate 
definite precursors or early lesions in sporadic cases. Notwithstanding these 
difficulties, however, there is now sufficient evidence, which has been extensively 
reviewed elsewhere (3), showing that STIC or a small tubal mucosal HGSC is present 
in the majority of sporadic HGSCs when the tubes can be identified grossly. There is 
also important recent evidence that STIC or a small tubal mucosal invasive lesion is 
present in virtually all cases of HGSC discovered as early incidental lesions following 
surgery carried out for unrelated indications (3).  
 
The clonal relationship between STIC and co-existing HGSC has also been difficult 
to establish until recently, for the reasons outlined above. HGSC is characterized by a 
tremendous degree of intra-tumoral genomic diversity partially due to defects in the 
function of genes involved in DNA repair mechanisms, such as the homologous 
recombination pathway (5). Despite this diversity, which arises early during 
oncogenesis, the tumors involving different sites in a patient with HGSC have been 
demonstrated to be clonally related, not only at presentation but also in disease 
recurrences. Mutations in TP53 are known to be the earliest and founding molecular 
event in HGSC, being present in 97% of cases (6); the demonstration of identical 
TP53 mutations in tumor sampled from different sites is compelling evidence of 
origin from a single clone. More recent work has established that STICs harbor TP53 
mutations that are identical to the ovarian and extra-adnexal disease foci (7). 
Although proposed as a theoretical possibility, there is absolutely no evidence to 
support multicentric origin in HGSC.  
 
A further possibility, which has been put forward to question the tubal origin of most 
cases of HGSC, is that the tube could be involved as a result of metastasis. However, 
this possibility is also allayed by multiple lines of evidence: STIC lesions have been 
demonstrated to show shortened telomeres in comparison to their invasive 
counterparts, as would be expected from a precursor-carcinoma relationship (8). An 
elegant high-resolution study incorporating phylogenetic mapping of lesions from 
different sites showed tubal mucosal tumour to be the clonal ancestor of tumor at 
other sites (9). In the recently reported series of incidental HGSC mentioned above, 
all cases confined to a single site, before any metastatic spread has occurred, are 
located in the fallopian tube (3). 
 
A major impediment to our acceptance of tubal origin has been the simplistic 
conventional approach of assigning primary site on the basis of tumor size. However, 
the ovary frequently harbors metastases whose size exceeds that of the primary tumor, 
as classically exemplified by metastatic gastric signet-ring carcinoma (Krukenberg 
tumor), but also by metastases of appendiceal, colorectal, hepatobiliary and cervical 
origin. Tubal HGSC appears to be yet another example of this phenomenon. It is 
widely recognized that, like endometrial serous intraepithelial carcinoma (the 
postulated precursor of uterine serous carcinoma), and unlike more indolent precursor 
lesions such as CIN3/HSIL, this disease is capable of metastasizing while still 
intraepithelial, by exfoliation onto peritoneal and ovarian surfaces. 
 
Consensus Statement 
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We strongly believe it is time to acknowledge the compelling evidence that the 
fallopian tube is the site of origin of most HGSCs and reflect this in our clinical 
practice. We believe it is essential to implement this worldwide because of the 
significant variation in current practice; some regions currently classify most HGSCs 
as tubal in origin while others still classify the majority as primary ovarian neoplasms.  
The increasing use of chemotherapy rather than surgery as the initial treatment for 
those with stage IIIC/IV disease can also confound disease classification as treatment 
decisions and classification are decided by imaging and biopsy alone, with potential 
for larger numbers of cases being classified as PPC. This move should be preceded by 
appropriate dissemination of this decision to all stakeholders including cancer 
registries as well as healthcare commissioners and providers, including insurers. The 
term ‘tubo-ovarian HGSC’ is recommended as a diagnostic term, to distinguish this 
disease clearly from uterine serous and ovarian low-grade serous carcinomas; this 
should take into account all clinical and pathological parameters, including history, 
clinical, imaging and surgical findings, and morphology with immunohistochemistry 
for WT1, p53 and other markers as appropriate in routine practice. We propose that 
the default assignment of the majority of cases of HGSC as ovarian should be 
discarded and recommend the use of the following criteria for site assignment in 
HGSC (summarized in Table 1): 
 
• Primary site should be assigned as tubal in the presence of STIC or invasive 
mucosal carcinoma in the fallopian tube, or when the tube is partly or fully 
incorporated and inseparable from a tubo-ovarian mass. 
• Primary site should be assigned as ovarian only when there is ovarian 
involvement and the tubes are clearly visible, have been dissected away from 
the surface of the ovaries, fully examined by a standardized SEE-FIM protocol 
and neither STIC nor invasive mucosal carcinoma is present in either tube. 
• Primary site should be assigned as peritoneal only when both tubes and both 
ovaries are grossly and microscopically normal; this diagnosis should only be 
made on cases undergoing primary surgery and after complete examination of 
both tubes and both ovaries using a standard protocol. 
• In cases diagnosed on an omental/peritoneal biopsy or a cytological sample 
and where primary surgery is not undertaken, the presumed primary site 
should be assigned as tubo-ovarian. By the 2014 WHO criteria, PPC is likely 
to become vanishingly rare, making it unnecessary to include this as part of 
the differential diagnosis. 
• Chemotherapy alters disease distribution; in most cases there is sufficient 
disease remaining to enable categorization using the above criteria, but those 
with no residual disease should also be assigned as tubo-ovarian.   
• Site assignment as ‘undesignated’ should be avoided as far as possible. 
 
A uniform approach to site assignment in HGSC is recommended by the International 
Collaboration on Cancer Reporting (ICCR) (10), which has incorporated most of the 
criteria listed above in their dataset on ovarian, tubal and primary peritoneal cancer. 
Using an earlier modification of the criteria listed above, in 53 prospectively studied 
chemo-naive cases of HGSC with unknown genetic status, 83% were classified as 
tubal, 17% as ovarian and none as peritoneal primaries (3). The protocol we present 
here has wider application than that recommended in the ICCR dataset, including 
guidance for cases diagnosed on small samples and following chemotherapy. 
Adopting a uniform approach worldwide will ensure accurate data collection for 
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comparing disease outcomes in routine practice and clinical trials. This will also 
promote wider understanding of the nature of this disease and the use of standardized 
pathology protocols in specimen dissection and reporting. This may in turn pave the 
way for developing effective ovary-conserving preventative strategies in this fatal 
disease; this is less likely to happen if we continue to consider most HGSCs as being 
of ovarian origin. 
 
 
 
Table 1: Criteria for assignment of primary site in Tubo-Ovarian HGSC 
 
Criteria Primary site Comment 
STIC present Fallopian tube Regardless of presence and 
size of ovarian and 
peritoneal disease 
Invasive mucosal 
carcinoma in tube, with or 
without STIC 
Fallopian tube Regardless of presence and 
size of ovarian and 
peritoneal disease 
Fallopian tube partially or 
entirely incorporated into 
tubo-ovarian mass 
Fallopian tube Regardless of presence and 
size of ovarian and 
peritoneal disease 
No STIC or invasive 
mucosal carcinoma in 
either tube in presence of 
ovarian mass or 
microscopic ovarian 
involvement 
Ovary Both tubes should be 
clearly visible and fully 
examined by a 
standardized SEE-FIM 
protocol. 
 
Regardless of presence and 
size of peritoneal disease 
Both tubes and both 
ovaries grossly and 
microscopically normal 
(when examined entirely) 
or involved by benign 
process in presence of 
peritoneal HGSC 
Primary peritoneal HGSC As recommended in WHO 
blue book 20142 
 
This diagnosis should only 
be made in specimens 
removed at primary 
surgery prior to any 
chemotherapy; see below 
for samples following 
chemotherapy. 
HGSC diagnosed on small 
sample, peritoneal/ 
omental biopsy or 
cytology  
Tubo-ovarian Note: this should be 
supported by 
clinicopathological 
findings including 
immunohistochemistry to 
exclude mimics, 
principally uterine serous 
carcinoma 
Post-chemotherapy with 
residual disease 
As above  
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Post-chemotherapy with 
no residual disease 
Tubo-ovarian  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure Legends 
Figure 1: Conventional tubal sampling; in the absence of a specific indication only 
representative single sections are taken from structures that are macroscopically 
normal. 1A: This is an essentially normal ovary and fallopian tube. 1B: In the past 
only a single transverse section was taken from the mid portion of the tube. 
 
Figure 2: SEE-FIM protocol for detailed examination of macroscopically normal 
fallopian tubes in prophylactic salpingo-oophorectomies and in familial and sporadic 
cases of HGSC. 2A: The tube is dissected away from the ovary. 2B: The fimbrial end 
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(arrow), comprising the distal 2cm or so, is separated from the rest of the length of the 
tube. 2C: The fimbrial end is sliced longitudinally in 4 or more slices. 2D: The rest of 
the tube is sliced in transverse slices. All of the tissue is processed and examined 
histologically. 
 
Figure 3: Microscopic tubal carcinoma identified in fimbrial mucosa. 
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